TRACER (S1415CD) NEWSLETTER









June 2018

STUDY UPDATES

★ As of 06/25/2018, we have 1,887 patients registered across ALL 45 components

THANK YOU TO OUR TOP ACCRUERS

CONGRATULATIONS TO ILLINOIS CANCER CARE IN PEORIA, IL FOR BEING OUR FIRST INTERVENTION SITE TO REACH 100% ACCRUAL!

These sites have reached at least 75% of their overall accrual:

- **★** St. Luke's Mountain States Tumor Institute in Boise, ID
- **★ Geisinger Medical Center in Danville, PA**
- **★** Sanford Medical Center in Fargo, ND

These sites have reached at least 90% of their overall accrual:

- **★** John H. Stroger Jr. Hospital of Cook County in Chicago, IL
- **★** Cancer Care Specialists of Central Illinois in Decatur, IL
- ★ Carle Cancer Center in Urbana, IL

MEDICAL RECORD REVIEW TIMING

Date of Medical Record Review on the 6 Month Status Update, 6 Month Febrile Neutropenia Log, and 12 Month Status Update forms should be on or after the day the patient reaches 6 and 12 months on study.

TRACER ACCRUAL BY STUDY ARM

TrACER: Overall Accrual by Study Arm


Study Arm	Patients Registered (% of Overall Accrual Goal)	Accrual Goal
Cohort	505 (65%)	780
Usual Care	339 (43%)	792
Intervention Arm 3	597 (50%)	1188
Intervention Arm 4	446 (37%)	1188

Updated 6-25-2018


TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

This pragmatic trial is designed to test an intervention to increase compliance with guidelines, and generate evidence to assess effectiveness of Primary Prophylactic CSF (PP-CSF) on reducing rates of FN for patients receiving intermediate-risk chemotherapy regimens. TrACER is the first trial of its kind and is sponsored by SWOG, a part of the National Clinical Trials Network. The trial is led by Dr. Scott Ramsey at HICOR and funded in part by PCORI.

TrACER Total Accrual as of June 25, 2018



TrACER Accrual in the Past 12 Months



Contact Us